• Astellas Pharma Inc., of Tokyo, said the FDA's Reproductive Health Drugs Advisory Committee voted 7 to 4, with one abstention, that the overall risk/benefit assessment supported approval of mirabegron (YM178) in overactive bladder. The FDA is not bound to follow the recommendation of advisory panels, but the agency generally does so. Mirabegron's PDUFA date is June 29.